Irish-German medtech firm OneProjects bags €11m in Series A
Summary
OneProjects has raised €11m in Series A to support the development of its Verafeye technology, which is designed to treat atrial fibrillation. This investment will help us to further build our team in Dublin and Munich, advance product development and ultimately achieve our goal of helping physicians provide a far better treatment for patients suffering from AFib.” He said that the backing of LSP, Atlantic Bridge Ventures and Enterprise Ireland brings “decades of successful experience” in life sciences to OneProjects. “We are extremely optimistic and hope to have our products in the market making a huge difference to patients and the healthcare system in the not too distant future.” Lahart explained that he met his co-founder, Hennersperger, at BioInnovate at NUI Galway. That’s the genesis and that’s where I met Christoph.” After completing the BioInnovate programme, the start-up secured Enterprise Ireland commercialisation funding, which brought it to Trinity College Dublin. The company is now headquartered in Dublin, with all of its operations, finance, clinical, quality and regulatory work handled in the Irish capital.